新闻
-
宋韵成章·岁华同庆!长鹿2026国庆游园盛典启幕
一笔丹青绘盛世,千年宋韵贺华诞。2026年国庆黄金周,佛山长鹿旅游休博园重磅打造“宋韵成章・岁华同庆”全域主题游园活动,把景区实景化作可游、可赏、可沉浸的动态古画,白天沉浸式逛大宋市井、赏国风百戏,夜间...
-
「巅峰性能旗舰」一加 16 定档 10 月 12 日:性能...
10 月 8 日,一加宣布「巅峰性能旗舰」一加 16 首批支持《三角洲行动》原生 185FPS + 高清画质模式,打造行业最强 185 超高帧游戏生态。新机将于 10 月 12 日正式发布,搭载第六代骁龙 8 超级至尊版与全新一代「...
-
深圳硬科技企业突围|赛诺动力破解灵巧手精密动力...
本报讯 近日,第十三届深圳宝安创新创业大赛圆满收官,赛诺动力(深圳)有限公司成功摘得人工智能赛道冠军。赛诺动力,作为全球领先的精密动力传动技术及解决方案供应商,企业将人形机器人灵巧手作为核心落地场景...
-
鱼戏中秋・人月团圆|2026 长鹿首届鱼灯文化节启幕...
月满中秋,文脉传续。2026年中秋假期,佛山长鹿旅游休博园以有着六百年历史的顺德非遗鱼灯为主题,举办首届“鱼戏中秋・人月团圆”鱼灯文化节。活动于9月25日至27日举办,打造众多沉浸式主题活动,集非遗手作、古风...
-
上海8小时耐力赛 天丝集团红牛品牌以持久能量连接...
9月25日至27日,2026上海8小时耐力赛在上海国际赛车场举行并落下帷幕。作为国内赛道规格最高的本土耐力赛事,本届比赛共有25辆赛车报名参赛,涵盖GT3、GTS和GTC三个组别,其中GT3组别以17辆赛车的参赛规模成为竞争最...
A Historic Breakthrough! Hymon® Pan-Cancer Screening Test Kit Secures FDA’s Second Global Pan-Cancer Early Screening “Breakthrough Device Designation”
发布时间:2026/06/24 新闻 浏览:208
Global cancer early screening has reached a milestone—with the city “Suzhou, China” now twice inscribed on the official US FDA website by the same Chinese company. On June 10, 2026, Suzhou-based HymonBio Co., Ltd. announced their independently-developed “Hymon® Pan-Cancer Screening Test Kit” has officially received the US FDA Breakthrough Device Designation. This marks not only the second such designation awarded by the FDA globally in the pan-cancer early screening sector but also the first time a Chinese product has achieved this prestigious honor.

Previously, the only product worldwide to receive this designation was Galleri, developed by the U.S. company Grail (approved in 2019). In 2021, sequencing giant Illumina acquired Grail for a staggering $8 billion. Seven years later, this honor—often hailed as the “top-tier pass” for pan-cancer early screening—has finally come to China.
One of Only Two Worldwide: How Valuable Is This “Pass”?
The FDA’s “Breakthrough Device Designation” is not a standard regulatory approval; rather, it is reserved for innovative technologies with the potential to revolutionize the diagnosis or treatment of life-threatening or irreversibly debilitating conditions. As of the end of 2025, the FDA had granted only about 1,200 such designations across the entire medical device landscape. Notably, within the pan-cancer early screening sector—which features exceptionally high technological barriers, lengthy R&D cycles, and extremely rigorous clinical validation—Grail had previously been the sole recipient.
HymonBio Co., Ltd. has now secured the world’s second such designation, marking a pivotal shift for China in the pan-cancer early screening field—a transition from “technology follower” to “original innovator.” More importantly, this achievement demonstrates the “Hymon® Pan-Cancer Screening Test Kit” has reached a world-class level in terms of technological innovation, clinical value, and scientific rigor, thereby paving a fast track for its entry into the U.S. market.
Technological Disruption: Defeating Expensive NGS with “PCR + AI”
Grail’s Galleri uses NGS (next-generation sequencing) technology. While NGS is cutting-edge, it requires expensive equipment, complex procedures, and costly reagents, with per-test prices remaining prohibitively high, severely hindering widespread adoption.
HymonBio has forged an entirely new technological path. The “Hymon® Pan-Cancer Screening Test Kit” deeply integrates artificial intelligence (AI) with classic PCR technology (polymerase chain reaction—a mature, Nobel Prize-winning technique). Based on methylation-specific PCR and proprietary AI algorithms, the product performs a multi-dimensional assessment of abnormal methylation levels in the test data. By simply drawing a single 5ml tube of venous blood, it enables precise early screening for 28 types of highly prevalent and lethal cancers using standard PCR equipment found in the clinical laboratories of ordinary hospitals.

From “Exorbitant Screening” to “Affordable for All”
Compared to NGS-based methods that rely on expensive sequencers and imported reagents, the AI + PCR technological route adopted by the “Hymon® Pan-Cancer Screening Test Kit” offers a cost advantage of orders of magnitude. Public data indicates that the Galleri test from the US-based company Grail costs over $1,000 per unit; in contrast, the “Hymon® Pan-Cancer Screening Test Kit” achieves a significant reduction in testing costs while maintaining high performance—pricing it well below mainstream international counterparts—thereby truly delivering a solution that is both accurate and affordable.
This marks a shift for pan-cancer early screening: moving from a “luxury affordable only to the few” to an “an accessible tool for everyone.” Dr. Tammy Tan, Chairman of HymonBio, stated: “Our goal is not merely to ensure accuracy in early cancer screening, but to make it affordable for everyone. Only by effectively translating technology into accessible medical services can we fundamentally alter the predicament of late-stage cancer detection and the resulting treatment challenges.”
A New Bellwether for Global Capital: Chinese Innovation Undergoing Revaluation
In 2019, after Grail secured the first “Breakthrough Device” designation for a pan-cancer early screening test, it sparked a frenzy of investor enthusiasm, ultimately leading to its $8 billion acquisition by Illumina in 2021. This classic case of “valuation driven by regulatory designation” remains a benchmark in the global biotechnology sector. Now, as one of only two pan-cancer early screening products worldwide with FDA breakthrough designation, the “Hymon® Pan-Cancer Screening Test Kit” holds immense commercial value and strategic significance.
Even more noteworthy is that global capital’s valuation of the pan-cancer early screening track has long since moved beyond “waiting for formal FDA approval.” Historic deals—such as Abbott’s $21 billion acquisition of Exact Sciences—demonstrate that industry giants view the strategic value of this sector as the ultimate certainty. HymonBio has not only secured a foothold in this arena but also holds the “premium pass” issued by the FDA; this development promises to serve as a key indicator prompting global capital to re-examine and re-evaluate the value of Chinese pharmaceutical innovation.
Nine Years of Sharpening a Sword: A Chinese Solution Illuminating the Global Fight Against Cancer
From receiving EU CE certification in 2022 to passing the rigorous FDA review and securing Breakthrough Device Designation in 2026, HymonBio has devoted nine years to intensive R&D, ultimately achieving a pioneering “zero-to-one” breakthrough for China in the field of pan-cancer early screening. The “Hymon® Pan-Cancer Screening Test Kit” not only offers a beacon of hope for early cancer detection to hundreds of millions of high-risk individuals worldwide but also—through its homegrown technology and a strategy of accessible, precision screening—provides the global fight against cancer with a highly cost-effective “Chinese solution.”

(Dr. Tan Miao, Chairman of HymonBio Co., Ltd., giving a lecture at the University of Leeds, UK)
Dr. Tammy Tan, Chairman of HymonBio, stated that the company will continue to deepen its focus on early cancer screening and precision medicine. By accelerating the clinical translation of more “zero-to-one” breakthroughs for the benefit of the public, HymonBio aims to contribute Chinese technological strength to the “Healthy China” initiative and the global cause of public health.